Lilly’s Mounjaro, based on the molecule tirzepatide, has enjoyed a first-mover advantage in India. The drug targets both GIP and GLP-1 receptors and has demonstrated weight loss of up to 23 per cent ...

GP in many parts of England are having explain to eligible patients that tirzepatide (Mounjaro) cannot be prescribed in ...

In a new TikTok video, the consultant and professor explains who's really eligible and why BMI isn't the full story ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Novo Nordisk launches Wegovy in India, expanding GLP-1 obesity drug market. The product competes with Eli Lilly's Mounjaro ...

With the weight-loss blockbuster drug Wegovy, now in India, renowned endocrinologist and diabetologist Dr. Ambrish Mithal ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

Mounjaro was launched in India earlier this year, while many leading multinational pharma companies are in the race to ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

As India becomes the new and latest nation witnessing the for weight-loss drugs frenzy, Novo Nordisk’s Wegovy challenges Eli ...